Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153907 · ClinicalTrials.gov registry record · Phase 1
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00153907 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00153907, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.
Interventions
- DRUG Capecitabine
- DRUG Navelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153907
The ClinicalTrials.gov registry entry for NCT00153907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00153907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153907 about?
NCT00153907 is a clinical study titled "Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer". The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.
What is the current status of trial NCT00153907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00153907?
The interventions under investigation include: Capecitabine (DRUG), Navelbine (DRUG).
Who is sponsoring clinical trial NCT00153907?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.